Form 4: Pliant Therapeutics Director Darren Cline Granted 30,000 Stock Options

Pliant Therapeutics, Inc. Director Darren Cline was granted 30,000 stock options with an exercise price of $1.61, vesting over approximately one year, as disclosed in a recent SEC Form 4 filing.

Summary

• Darren S. Cline, a Director of Pliant Therapeutics, Inc. (PLRX), was granted 30,000 stock options.
• The options have an exercise price of $1.61 per share.
• The grant date for these options was June 5, 2025.
• The options are exercisable until their expiration date of June 5, 2035.
• The vesting schedule for the options is staggered: 25% on October 1, 2025; 25% on January 1, 2026; 25% on April 1, 2026; and the final 25% on the earlier of June 5, 2026, or the next annual meeting of stockholders, contingent on Mr. Cline's continued service as a Director.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event for the individual recipient, aligning their interests with the company's long-term performance. For the company, it's a standard compensation practice, not inherently positive or negative for immediate financial results, but contributes to governance and incentive alignment.

Positives

• The grant of 30,000 stock options to Director Darren S. Cline aligns his interests with long-term shareholder value creation.
• The options have a 10-year expiration period (until June 5, 2035), providing a long window for potential value realization.

Negatives

• The exercise price of $1.61 means the options only have value if the stock price rises above this level.
• The vesting schedule requires continued service, meaning the options could be forfeited if the director's service ceases before full vesting.

Risks

• The Limited Power of Attorney document includes an indemnification clause stating that the undersigned (Darren Cline) agrees to indemnify the attorneys-in-fact and the Company from any demand, damage, loss, cost, or expense arising from any false or misleading information provided by the undersigned to the attorneys-in-fact.

Future Outlook

The document details the vesting schedule for the granted stock options, indicating future dates when portions of the options will become exercisable, contingent on the director's continued service.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically an equity grant to a director, which is a common practice in the biotechnology and pharmaceutical industries to align executive and director incentives with shareholder interests. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Related Party Transactions

• The grant of 30,000 stock options to Darren S. Cline, a Director of Pliant Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options represents potential future dilution if exercised, but also aligns the director's incentives with increasing shareholder value. The impact of 30,000 options on overall outstanding shares is likely minimal.
• Director (Darren S. Cline): Receives a significant equity incentive, tying a portion of his compensation to the company's stock performance and providing a long-term incentive to contribute to the company's success.

Next Steps

• Continued service of Darren S. Cline as a Director of Pliant Therapeutics, Inc. to ensure full vesting of options.
• Future vesting of options on October 1, 2025, January 1, 2026, April 1, 2026, and the earlier of June 5, 2026, or the next annual meeting of stockholders.

Key Dates

Keywords

Pliant Therapeutics, PLRX, Darren Cline, Stock Options, SEC Form 4, Insider Transaction, Director Compensation, Equity Grant, Vesting Schedule, Biotechnology, Pharmaceuticals